AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01816906 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Footwear: MCP
Description: One group of patients will receive footwear with MCP insoles
Study NCT03125902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 90 mg/m\^2 via IV infusion on Days 1, 8, and 15 of every 28-day cycle.
Study NCT00525629 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Walnuts
Description: 48 Grams of Walnuts Daily
Study NCT00525629 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control Diet with No Walnuts
Study NCT01533467 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Perineal protection device
Description: Use of the device during delivery and inspection afterwards to see the tears.
Study NCT02966795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir
Description: Fixed-dose combination tablets taken orally once a day.
Study NCT02066506 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: asymptomatic group
Description: 2 visits with MRI
Study NCT02066506 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: symptomatic group
Description: 2 visits with MRI
Study NCT03043027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal bupivicaine
Description: local anesthetic
Study NCT03125902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 90 mg/m\^2 via IV infusion on Days 1, 8, and 15 of every 28-day cycle.
Study NCT01034618 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein hydrolyzation
Study NCT01034618 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Protein hydrolyzation
Study NCT00644618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: a 30-minute intravenous infusions of gemcitabine 1,000 mg/m2 weekly×7, followed by a 1-week pause, and then weekly×3
Study NCT04589117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive writing
Description: The 4-week study intervention will invite participants through a progression of expressive writing exercises designed to support emotional expression and enhance personal resilience. Weekly instruction writing sessions will be conducted via Zoom. The sessions will not be recorded, but participants who cannot attend the sessions live (or prefer not to, for any reason) will receive each week's instructions and prompts via email.~The progression of writing exercises flows as follows:~* Week 1: Writing to expressive difficult emotions~* Week 2: Writing to cultivate compassion \& forgiveness~* Week 3: Writing to nurture positive emotions~* Week 4: Writing to invite insight, perspective, \& growth
Study NCT03043027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: local anesthetic
Study NCT03043027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: saline injection
Study NCT03913650 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: 0.25% bupivacaine
Description: nerve block procedure will be decided by patients' will for post-op pain
Study NCT03310099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increasing daily unsaturated fatty acid consumption
Description: Investigators will provide participant with detailed information about the consumption of food rich in unsaturated fatty acids (UFA) like extra-virgin olive oil, canola oil or mixed nuts, and they will provide specific recommendations based on the participant's diet. The investigators will follow up with a weekly phone call to assure that the dietary recommendations are clear and that the participants can integrate the suggestions into their daily diets.
Study NCT00644618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 125I brachytherapy PLUS gemcitabine
Description: 125I brachytherapy PLUS a 30-minute intravenous infusions of gemcitabine 1,000 mg/m2 weekly×7, followed by a 1-week pause, and then weekly×3
Study NCT02653495 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Influenza vaccine administered intramuscularly (IM), 1 time only, on visit 3
Study NCT02790632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteral Nimodipine
Description: Enteral Nimodipine capsules or tablets administered for up to 21 days and single intraventricular administration of saline via EVD
Study NCT02779426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messages
Description: Daily text messages with information about atopic dermatitis and treatment reminders.
Study NCT01409772 — intervention group
Intervention type: DRUG
Intervention: Ethanol Lock
Description: Ethanol Lock
Study NCT04545086 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Based Education, Music Therapy
Description: Video Based Education and Music Therapy was given as a part of Interventions to relieve anxiety of patients undergoing Magnetic Resonance Imaging
Study NCT03913650 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% bupivacaine
Description: nerve block procedure will be decided by patients' will for post-op pain
Study NCT03222596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercise programme includes breathing and upper limbs exercises.
Study NCT03251040 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Autologous activated fibrin sealant
Description: Application of fibrin sealant
Study NCT01515475 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glasses
Description: Glasses will be prescribed at enrollment with the sphere cut symmetrically by 1.00D and full cylinder correction.
Study NCT01515475 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Glasses
Description: Glasses will be prescribed at enrollment with the sphere cut symmetrically by 1.00D and full cylinder correction.
Study NCT02646332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (dexlan+amox+clar+metr)+(dexlan+amox)
Description: a 7-day quadruple regimen with dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with dexlansoprazole MR 60 mg once daily and amoxicillin 1 g twice daily
Study NCT02646332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexlan+clarith+amox+metro
Description: dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily for 14 days
Study NCT04165772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSR-042 or Dostarlimab
Description: Patients will be given TSR-042/Dostarlimab at a dose of 500mg IV, over 30 minutes Q 3 weeks.
Study NCT04165772 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TSR-042 or Dostarlimab
Description: Patients will be given TSR-042/Dostarlimab at a dose of 500mg IV, over 30 minutes Q 3 weeks.
Study NCT04165772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine or 5-FU
Description: Capecitabine 825mg/m2 BID concurrently with radiation per standard radiation guidelines. If patient is unable to tolerate oral medication, infusional 5-FU is an acceptable alternative.
Study NCT01740089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Algeron
Description: 1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously
Study NCT01740089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PegIntron
Description: 1.5 μg/kg/week subcutaneously in combination with ribavirin
Study NCT04165772 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Description: The radiation dose is 5400 cGy to the tumor and surrounding nodes 4700 cGy to the pelvis, with an integrated boost to the primary tumor and involved nodes of receiving 5400cGy in 27fx.
Study NCT02865460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
Study NCT00253721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: All levels: Every 4 weeks for up to one year~Dose Escalation Plan:~Level 1: 4mg/m2/day x 2 days~Level 2: 6mg/m2/day x 2 days~Level 3: 8mg/m2/day x 2 days~Level 4: 10mg/m2/day x 2 days~Level 5: 12mg/m2/day x 2 days
Study NCT01563224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen 10mg
Description: Baclofen 10mg single dose po
Study NCT01563224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen 60mg
Description: Baclofen 60mg single dose po
Study NCT01573338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roniciclib (BAY1000394)
Description: oral administration twice daily in a 3 days on/ 4 days off schedule. Starting dose will be 2.5 mg bid and dose will be escalated or de-escalated depending on dose limiting toxicity.
Study NCT01573338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m2 will be administered IV on Days 1, 2, and 3 of each 21 day cycle.
Study NCT01573338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2 will be administered IV on Day 1 of each 21 day cycle after the etoposide infusion is complete.
Study NCT01573338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered IV on Day 1 of each 21 day cycle. The dose of carboplatin will be determined for each cycle using the Calvert's formula, to yield an AUC of 5 (mg/mL) • min.
Study NCT00162318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab + Gefitinib
Description: IV solution + tablet, IV + oral, ERB (100 mg/m2, 200 mg/m2 + 250 mg/m2 IV) +GEF 250 mg tablet, ERB weekly/ GEF once daily, Until disease progression.
Study NCT03479918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-DA-EPOCH-21
Description: R-DA-EPOCH-21 treatment without auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
Study NCT03479918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-BL-M-04
Description: R-BL-M-04 treatment without auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
Study NCT03479918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-DA-EPOCH-21 + auto-SCT
Description: R-DA-EPOCH-21 treatment with auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
Study NCT03479918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-BL-M-04 + auto-SCT
Description: R-BL-M-04 treatment with auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
Study NCT00814749 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: midureteral sling
Description: midureteral sling
Study NCT00814749 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: surgical therapy or conservative
Description: midureteral sling or conservative; medication, physiotherapy
Study NCT04494399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1b
Description: 5-day course of daily subcutaneous injection of interferon β-1b 16 million IU
Study NCT04494399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 5-day course of oral ribavirin 400mg twice daily
Study NCT03430518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1.12g given IV on day 1 every 21 day cycle
Study NCT03430518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: 1.1 mg/m2 IV on day 8 of every 21 day cycle in the first 3 patients, then increased to 1.4mg/m2 IV on day 1 and day 8 of every 21 day cycle. If significant toxicity occurs in patients given the 1.1mg/m2 IV dose, then subsequent patients with receive eribulin 0.7mg/m2 IV on day 1 and day 8 of every 21 day cycle.
Study NCT02114515 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hospital usual care
Description: Written discharge instructions provided to patients prior to hospital discharge.
Study NCT02114515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hospital usual care
Description: Written discharge instructions provided to patients prior to hospital discharge.
Study NCT02114515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigator intervention
Description: A Patient Navigator will provide social support, literacy appropriate education, and act as a conduit between the patient and the patient's medical team
Study NCT02114515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-led telephone support line
Description: The peer-led telephone support line will provide social support, peer-to-peer coaching, and facilitate communication with the patient's medical care team.
Study NCT01661972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine and aflibercept
Description: Capecitabine given on days 1-14 and off days 15-21. Dose: Phase 1 cohort 1 850mg/m2 Phase 1 cohort 2 1000mg/m2, Phase 2 RPTD.~Aflibercept will be held constant at 6 mg/kg, given intravenously every 3 weeks.~Both agents will be administered on a 21-day cycle.
Study NCT03146026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Exercise Training
Description: The CET program was performed for 60 minutes with 5 minutes of warm-up and cool-down per day, 3 times a week for 12 weeks. Combined exercise consisted of 20 minutes of various resistant band exercises (Upper body: seated rows, biceps curl, shoulder flexion, elbow flexion, chest press; Lower body: hip flexion, hip extension, calf raise, leg press, squat) and 30 minutes of treadmill walking. The warm-up and cool down consisted of static stretching. Intensity of exercise was gradually increased from 40-50% heart rate reserve (HRR) in weeks 1-4, and to 60-70% HRR in weeks 9-12. Each training session was fully supervised by the researchers. Every subject wore a heart rate monitor during the whole training session so as to maintain the correct training intensity.
Study NCT01740089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 800-1400 mg/day orally
Study NCT01740089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 800-1400 mg/day orally
Study NCT03020498 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluzone
Description: Influenza Virus Vaccine Suspension for Intramuscular Injection
Study NCT03020498 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FluMist
Description: Influenza Virus Vaccine Live, Intranasal Intranasal Spray
Study NCT01472159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CGM Family Teamwork Intervention
Description: The family-focused behavioral intervention targets barriers associated with sustained CGM use in youth with type 1 diabetes. During months 1-18, families in the intervention group will participate in the intervention at each study visit for about an additional 30 minutes.
Study NCT00506896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intraarticular injection
Description: Triamcinolone hexacetonide 60mg(3ml)by intraarticular injection Triamcinolone acetonide 60mg (3ml)by intramuscular administration
Study NCT02060084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: a control group
Description: the same dose of luke warm water
Study NCT02060084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: a probiotic-supplemented group
Description: was orally administered starting from day 2 after birth, at a dose of 0.5g (the numbers of Long Bifidobacterium, Lactobacillus acidophilus and Enterococcus faecalis in live>0.5\*107CFU), twice per day, for 2 weeks
Study NCT02751957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Start Denver Model
Description: The Early Start Denver Model is an evidence based, behavioral intervention for young children who have an autism spectrum disorder. It is a behavioral treatment informed by the principles of applied behavior analysis.
Study NCT00366470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A. 100,000 IU Cholecalciferol per dose of 3.3ml
Description: 100,000 IU Cholecalciferol in 3.3ml Migliol (Carrier) oil, once every two weeks for 2 Months
Study NCT00366470 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: B. Migliol Oil without Cholecalciferol
Description: 3.3 ml Migliol Oil, every two weeks for two months
Study NCT01171053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT
Description: Internet-delivered cognitive behavioral therapy with therapist support.
Study NCT01171053 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Therapist support
Description: Weekly therapist support without CBT-interventions
Study NCT04396938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Active Drug Capsule
Study NCT04396938 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo Capsule
Study NCT02068053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] BMS-986020
Study NCT03958526 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active tDCS
Description: Patients in active group will receive 10 sessions of anodal tDCS delivered over primary motor cortex (M1) contralateral to the most painful side with a constant current of 2 miliAmpers for 20 minutes.
Study NCT03958526 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham tDCS
Description: Same protocol (electrode montage,session duration) will be used for sham stimulation. But the device won't be active for full 20 minutes.
Study NCT02120807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab
Study NCT02120807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT02120807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Study NCT01868061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.
Study NCT01868061 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.
Study NCT01868061 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
Study NCT03864159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suction cups
Description: The technique will be performed with the subject sitting on the floor, placing the Foam roller on the back of the thigh, requesting the athlete to perform cranial and caudal movements during the established time. The stretching exercise with the Foam roller will be done during 2 minutes in each member. The intervention through the suction cups will be performed with the subject in prone position, on the stretcher. The suckers are placed in the proximal part where the posterior musculature of the leg originates and in the distal part of the biceps femoris, semitendinosus and semimembranous insertion. This administration of the suckers will be applied during a period of 7 minutes in each member.
Study NCT03864159 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Foam roller
Description: Each session will last 18 minutes, taking place two days a week, in a period of 4 weeks. The intervention will be carried out before starting the training session. The intervention through the self-administration of Foam roller has the objective of increasing the flexibility of the isquitibial musculature. The technique will be performed with the subject sitting on the floor, placing the Foam roller on the back of the thigh, requesting the athlete to perform cranial and caudal movements during the established time. The stretching exercise with the Foam roller will be done during 2 minutes in each member.
Study NCT01866800 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Renal Guard
Description: Renal Guard
Study NCT01866800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Treatment
Description: Saline and N-acetylcysteine
Study NCT01563224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo
Study NCT03438591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic 4196 lead
Description: Cerclage-CRT pacing with Medtronic 4196 lead (Attain Ability Lead)
Study NCT01866800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Saline and N-acetylcysteine